DK1392713T3 - Lever-X-receptoragonister - Google Patents

Lever-X-receptoragonister

Info

Publication number
DK1392713T3
DK1392713T3 DK02731581T DK02731581T DK1392713T3 DK 1392713 T3 DK1392713 T3 DK 1392713T3 DK 02731581 T DK02731581 T DK 02731581T DK 02731581 T DK02731581 T DK 02731581T DK 1392713 T3 DK1392713 T3 DK 1392713T3
Authority
DK
Denmark
Prior art keywords
sub
alkyl
haloalkyl
independently
liver
Prior art date
Application number
DK02731581T
Other languages
Danish (da)
English (en)
Inventor
Shutsung Liao
Ching Song
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Application granted granted Critical
Publication of DK1392713T3 publication Critical patent/DK1392713T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK02731581T 2001-05-03 2002-05-02 Lever-X-receptoragonister DK1392713T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28864301P 2001-05-03 2001-05-03
PCT/US2002/013594 WO2002090375A2 (en) 2001-05-03 2002-05-02 Liver x receptor agonists

Publications (1)

Publication Number Publication Date
DK1392713T3 true DK1392713T3 (da) 2008-02-18

Family

ID=23108009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02731581T DK1392713T3 (da) 2001-05-03 2002-05-02 Lever-X-receptoragonister

Country Status (11)

Country Link
US (1) US7012069B2 (de)
EP (1) EP1392713B1 (de)
JP (1) JP4309661B2 (de)
CN (1) CN100360550C (de)
AT (1) ATE375994T1 (de)
CA (1) CA2446314C (de)
DE (1) DE60223020T2 (de)
DK (1) DK1392713T3 (de)
ES (1) ES2296928T3 (de)
PT (1) PT1392713E (de)
WO (1) WO2002090375A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
AU775630B2 (en) * 1999-04-30 2004-08-05 Arch Development Corporation Steroid derivatives
JP2005508281A (ja) * 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
WO2003039480A2 (en) * 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
EP1511483A4 (de) * 2002-03-27 2009-03-18 Smithkline Beecham Corp Verfahren zur behandlung mit lxr-modulatoren
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
WO2007121462A2 (en) * 2006-04-18 2007-10-25 Bristol-Myers Squibb Company CRYSTAL STRUCTURE OF LXR-ß AND LXR-α
EP2457567B1 (de) 2007-09-19 2015-12-30 Nagoya Industrial Science Research Institute Wirkstoff mit Aktivität ähnlich des neurotrophen Faktors
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
CN101592648A (zh) * 2008-05-30 2009-12-02 国鼎生物科技股份有限公司 肝脏x受体激动剂的筛选方法
JP2013500986A (ja) * 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EP2759295A1 (de) 2013-01-29 2014-07-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Schaumzellenspezifischer Leber-X-Rezeptor-(LXR)-alpha-Agonist, SIRT1-Hemmer sowie p300-Hemmer als pharmazeutische aktive Wirkstoffe
EP3932932A1 (de) * 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroaktive steroide und verfahren zur verwendung davon
JP2016193835A (ja) * 2013-09-04 2016-11-17 学校法人常翔学園 核内受容体肝臓ｘ受容体アゴニスト
TW202348234A (zh) 2013-12-24 2023-12-16 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
CA2991313C (en) 2015-07-06 2023-12-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2017240157B2 (en) 2016-04-01 2022-10-20 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HRP20220932T1 (hr) 2016-08-02 2022-10-28 Virginia Commonwealth University Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
NZ752732A (en) 2016-10-18 2024-08-30 Sage Therapeutics Inc Oxysterols and methods of use thereof
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
WO2021033766A1 (ja) * 2019-08-22 2021-02-25 国立大学法人お茶の水女子大学 ビタミンｄ活性を有するリトコール酸誘導体
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698853A (en) * 1951-08-11 1955-01-04 Monsanto Chemicals Oxidation of steroids
FR1482102A (fr) * 1966-03-31 1967-05-26 Centre Nat Rech Scient Nouveaux dérivés de stéroïdes et procédé de préparation
US3784598A (en) * 1972-01-20 1974-01-08 Ciba Geigy Corp Process for the conversion of a 3-hydroxy-5,6-oxido group of a steroid into a delta4-3-oxo group
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US4006172A (en) * 1976-04-26 1977-02-01 The Upjohn Company Process for 7-keto-Δ5 -steroids
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
US4125544A (en) * 1977-06-09 1978-11-14 G. D. Searle 20/22/23/24-Oxa-7-oxocholesterols and esters thereof
US4193930A (en) * 1977-08-29 1980-03-18 G. D. Searle & Co. 25-Alkyl-3β-hydroxycholest-5-en-7-ones and esters thereof
JPS563000A (en) * 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4639420A (en) * 1984-11-21 1987-01-27 Schaffner Carl P Method for the immunoanalysis of cholesterol epoxides
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
IT1212141B (it) * 1987-06-03 1989-11-08 So Ri Far S R L Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
WO1989003212A1 (en) * 1987-10-13 1989-04-20 Pfizer Inc. 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
IE72169B1 (en) 1989-11-17 1997-03-26 Asahi Glass Co Ltd Processes for producing 5-fluorobenzoic acids and their intermediates
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5333972A (en) * 1990-10-04 1994-08-02 Valenite Inc. Special boring insert
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
IT1255486B (it) * 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la taurina
US5482935A (en) * 1993-01-05 1996-01-09 American Home Product Corporation Anti-atherosclerotic use of 17 alpha-dihydroequilin
TW289757B (de) * 1993-05-08 1996-11-01 Hoechst Ag
IT1270853B (it) * 1993-05-20 1997-05-13 Sanofi Elf Procedimento per la preparazione di derivati taurocolanici
CN1055929C (zh) * 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
IT1274000B (it) * 1994-04-06 1997-07-14 Alfa Wassermann Spa Derivati di acidi biliari utili nella terapia della calcolosi biliare da colesterolo e nelle patologie indotte da colestasi
US6369247B1 (en) * 1994-05-19 2002-04-09 Merck & Co., Inc. Process for oxidation of steroidal compounds having allylic groups
CN1107299A (zh) * 1994-11-28 1995-08-30 蒋松林 一种新型药膳保健水果茶
US5583239A (en) * 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
DE19624342C1 (de) * 1996-06-19 1997-12-11 Walter Ag Schneidplatte und Fräser, insbesondere Kugelstirnfräser oder Kopierfräser
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
IL129297A (en) * 1998-07-13 2002-12-01 Iscar Ltd Tangential cutting insert
PT1108207E (pt) 1998-08-26 2008-08-06 Sensors For Med & Science Inc Dispositivos de sensores ópticos
JP2002532729A (ja) * 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US6465258B1 (en) * 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US6102630A (en) * 1999-01-12 2000-08-15 Tool Flo Manufacturing, Inc. Ball nose end mill insert
AU775630B2 (en) * 1999-04-30 2004-08-05 Arch Development Corporation Steroid derivatives
JP2005508281A (ja) * 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
WO2003086303A2 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists

Also Published As

Publication number Publication date
CA2446314C (en) 2011-02-22
DE60223020D1 (de) 2007-11-29
EP1392713A2 (de) 2004-03-03
DE60223020T2 (de) 2008-07-24
WO2002090375A2 (en) 2002-11-14
ES2296928T3 (es) 2008-05-01
CN100360550C (zh) 2008-01-09
WO2002090375A3 (en) 2003-12-18
ATE375994T1 (de) 2007-11-15
EP1392713B1 (de) 2007-10-17
CN1585777A (zh) 2005-02-23
PT1392713E (pt) 2008-01-25
JP4309661B2 (ja) 2009-08-05
WO2002090375A8 (en) 2004-05-27
US20020193357A1 (en) 2002-12-19
EP1392713A4 (de) 2004-11-17
CA2446314A1 (en) 2002-11-14
JP2005507855A (ja) 2005-03-24
US7012069B2 (en) 2006-03-14

Similar Documents

Publication Publication Date Title
DK1392713T3 (da) Lever-X-receptoragonister
FR17C0003I2 (fr) Steroides comme agonistes de fxr
BR9809398A (pt) Quinazolinonas que inibem a farnesil transferase
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
CY1107634T1 (el) Φαρμακευτικη συνθεση
BR0114136A (pt) Derivados de oxima e seu uso como ácidos latentes
IS6362A (is) Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni
DK1673338T3 (da) Forbindelser afledt af fedtsyrer, fremstilling og anvendelse
RS50574B (sr) (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline
BR9916198A (pt) Formulações pesticidas contendo semi-éster de sulfato de triestirilfenol alcoxilado neutralizado com tensoativos de amina alcoxilados
DE60202379D1 (de) Neuartige verbindungen
KR100366902B1 (ko) 섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
HK1094680A1 (en) Anti-inflammatory agents
ATE380172T1 (de) Benzylaminanalogen
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
DE60116514D1 (de) Amlodipin-hemimaleat
TR200300551T2 (tr) Agrokimyasal kompozisyon
DK1347960T3 (da) Fremgangsmåde til fremstilling af (+/-) trans-4-p-fluorphenyl-3-hydromethyl-1-methylpiperidin
SE0101323D0 (sv) New process
GB9914085D0 (en) New use
BR9811499A (pt) "derivados da 6-azauracila como inibidores da il-5"
DK1182199T3 (da) Fremgangsmåde til fremstilling af amicsyre
MXPA02001415A (es) Proceso para elaborar una formulacion de liberacion sostenida.
DK1360367T3 (da) Anvendelse af pigmenter som dispersionsstoffer